Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Marky1on Mar 08, 2020 10:59am

186 Views

Post# 30780371

Buyout

Please explain to me, somebody, since I am just a lowly student trying to pay off my student loans

if an offer to buy the company comes out...Don't the shareholders have a say, acceptance or refusal?

For me, I think the 346 technology is worth at least B$ USD..but who makes the final decision? Llets say there are only a small portion of outstanding shares unsold...let's say 5%

So a company buys those shares, far less than a majority of the entire shares outstanding ...so how do they take over said company

sorry for my ignorance
JM

Bullboard Posts

Changing Europe’s dependency on HREE from China